Title:
HIGH-CONCENTRATION ANTI-HER2 ANTIBODY PREPARATION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/019556
Kind Code:
A1
Abstract:
The present invention relates to a high-concentration anti-HER2 antibody preparation and use thereof. The antibody preparation of the present invention does not have an additional buffering agent, but has high-concentration protein self-buffering, so that the impact of histidine oxidation products such as aspartate and formamide on the activity of the antibody is reduced. The preparation can fully prevent protein aggregation, degradation, oxidation or denaturation and the like, so that the biological activity of effective components of the preparation is maintained, and the preparation is suitable for clinical use.
Inventors:
ZHOU BINGBING (CN)
ZHANG LE (CN)
CONG RIYUAN (CN)
DONG TING (CN)
FAN HECHAO (CN)
YANG MENGMENG (CN)
YAN MANG (CN)
WANG LE (CN)
AI XIANWEI (CN)
WANG GUIJIANG (CN)
LI DAOYUAN (CN)
WANG KEBO (CN)
WANG QINGMIN (CN)
SUN LIXIA (CN)
AN ZHENMING (CN)
LIU JUN (CN)
ZHANG LE (CN)
CONG RIYUAN (CN)
DONG TING (CN)
FAN HECHAO (CN)
YANG MENGMENG (CN)
YAN MANG (CN)
WANG LE (CN)
AI XIANWEI (CN)
WANG GUIJIANG (CN)
LI DAOYUAN (CN)
WANG KEBO (CN)
WANG QINGMIN (CN)
SUN LIXIA (CN)
AN ZHENMING (CN)
LIU JUN (CN)
Application Number:
PCT/CN2021/113798
Publication Date:
February 23, 2023
Filing Date:
August 20, 2021
Export Citation:
Assignee:
QILU PHARMACEUTICAL CO LTD (CN)
International Classes:
A61K39/395; A61K9/08; A61K47/18; A61K47/26; A61K47/42; A61P35/00
Foreign References:
| CN114129723A | 2022-03-04 | |||
| CN102573789A | 2012-07-11 | |||
| CN110167594A | 2019-08-23 | |||
| TW202123965A | 2021-07-01 | |||
| CN1539505A | 2004-10-27 |
Attorney, Agent or Firm:
BEIJING ORIGINTELLIGENCE IP LAW FIRM (CN)
Download PDF: